冠心病杂志

Coronary heart disease is the most common cause of death in the general population and in patients with ESRD. Both groups are subject to the same cardiovascular risk assessment and treatment approaches. Non-invasive coronary artery imaging has advanced, allowing for earlier diagnosis of subclinical disease. Medical care of coronary artery disease aims to alter the illness's natural course and alleviate angina symptoms. Despite the risks of stroke, myocardial infarction, and chest wound infection, coronary bypass surgery appears to be the preferred option in stable ESRD with multi vessel coronary artery disease.

For effective Atrial Fibrillation (AF) ablation, a transmural lesion must be created. In Contact Force-guided (CF) ablation for AF, the differences in lesion characteristics between conventional energy and High-Power Short-Duration (HPSD) settings remained unknown

Despite lowering Cardiovascular Disease (CVD) death rates, heart disease remains the primary cause of death. Family history of heart disease is a significant risk factor that has long been linked to heart disease. The INTERHEART (Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction) study was used to determine the relationship between Myocardial Infarction (MI) and parental history of MI. Shared genetic, environmental, and behavioural factors may contribute to an elevated risk of heart disease due to family history. With the early beginning of heart disease in the family and the number of persons affected, genetic factors play a larger role in the increased familial risk of heart disease. Genetic conditions, most commonly familial hypercholesterolemia, account for a small proportion of excess familial risk, but causes of most familial cases of heart disease remain unknown. Because a positive family history of early heart disease is a known risk factor for heart disease, it's crucial to assess its public health impact in terms of population prevalence of family history of heart disease, as well as the burden of heart disease attributed to family history. Because the survey is population-based, representative, and weighted, and collects information on heart disease, heart disease risk factors, and family history of premature heart disease, NHANES (The National Health and Nutrition Examination Survey) provides a unique opportunity to conduct such an analysis.

This article presents a current overview of our understanding of genetic contributions to the development of congenital cardiac disease. Since the year 2007 the publication of a paper on the genetic basis of congenital heart disease, new genomic tools have been widely available, drastically altering our understanding of the aetiology of congenital heart disease. New molecular testing techniques are discussed, as well as their use to congenital cardiac disease, both alone and in combination with other congenital defects or syndromes. The latest research on copy number variations, syndromes, RASopathies, and heterotaxy/ciliopathies is presented. New research findings using congenital heart disease models. This review is expected to provide timely information on the genetic aspects of congenital heart disease to a wide range of health-care professionals, including paediatric cardiologists, paediatricians, adult cardiologists, thoracic surgeons, obstetricians, geneticists, genetic counsellors, and other related clinicians.

Hypertension is a leading cause of early morbidity and mortality that can be avoided. People with hypertension and established cardiovascular disease are especially vulnerable; therefore lowering blood pressure below recommended levels could be beneficial. This technique has the potential to reduce cardiovascular mortality and morbidity, but it also has the potential to increase adverse events. In persons with hypertension and established cardiovascular disease, the ideal blood pressure target is uncertain. To see if 'lower' blood pressure targets (135 mmHg/85 mmHg) in the treatment of people with hypertension and a history of cardiovascular disease are associated with lower mortality and morbidity than' standard' blood pressure targets (140 mmHg to 160 mmHg/90 mmHg to 100 mmHg) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive disease). High blood pressure is common in persons who have heart or vascular disorders. In those with a history of cardiac or vascular problems, certain clinical guidelines propose a lower blood pressure goal (135 mmHg/85 mmHg or lower) than in those without (normal blood pressure goals are 140 mmHg to 160 mmHg systolic and 90 mmHg to 100 mmHg diastolic). It's uncertain whether the reduced targets result in improved overall health.